DE20203103U1 - Serotonin reuptake inhibitors - Google Patents
Serotonin reuptake inhibitorsInfo
- Publication number
- DE20203103U1 DE20203103U1 DE20203103U DE20203103U DE20203103U1 DE 20203103 U1 DE20203103 U1 DE 20203103U1 DE 20203103 U DE20203103 U DE 20203103U DE 20203103 U DE20203103 U DE 20203103U DE 20203103 U1 DE20203103 U1 DE 20203103U1
- Authority
- DE
- Germany
- Prior art keywords
- group
- compound
- carbomethoxy
- octane
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/753—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/44—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßtThe description text was not recorded electronically
Claims (17)
wobei:
R1 = COOCH3-, COR3-, niedere Alkyl-, niedere Alkenyl-, niedere Alkinyl-, CONHR4- oder COR6-Gruppe;
R2 = 6α-, 6β-, 7α- oder 7β-Substituent aus folgender Gruppe: H, OH, OR3, F, Cl, Br und NHR3;
X = CH2-, CHY-, CYY1-, CO-, O-, S-, SO-, SO2-Gruppe oder C = CX1Y, wobei das C-, O- oder S-Atom ein Bestandteil des Rings ist;
X1 = NR3-, CH2-, CHY-, CYY1-, CO-, O-, S-, SO-, SO2- oder NSO2R3-Gruppe;
R3 = H-, (CH2)nC6H4Y-, C6H4Y-, CHCH2-, niedere Alkyl-, niedere Alkenyl- oder nie dere Alkinylgruppe;
Y und Y1 = H-, Br-, Cl-, I-, F-, OH-, OCH3-, CF3-, NO2-, NH2-, CN-, NHCOCH3-, N(CH3)2-, (CH2)nCH3-, COCH3- oder C(CH3)3-Gruppe;
R4 = CH3-, CH2CH3- oder CH3SO2-Gruppe;
R6 = Morpholinyl- oder Piperidinylgruppe;
Ar = Phenyl-R5-, Naphthyl-R5-, Anthracenyl-R5-, Phenanthrenyl-R5- oder Diphenyl methoxy-R5-Gruppe;
R5 = Br-, Br-, CI-, I-, F-, OCH3-, GF3-, NO2-, NH2-, CN-, NHCOCH3-, N(CH3)2-, (CH2)nCH3-, COCH3-, C(CH3)3-, wobei n = 0-6, 4-F-, 4-Cl-, 4-I-, 2-F-, 2-Cl-, 2-I-, 3-F-, 3-Cl-, 3-I-, 3,4-diCl-, 3,4-diOH-, 3,4-diOAc-, 3,4-diOCH3-, 3-OH-4-Cl-, 3-OH-4-F-, 3-Cl-4-OH-, 3- F-4-OH-; niedere Alkyl-, niedere Alkoxy-, niedere Alkenyl-, niedere Alkinyl-, CO- (niederer Alkylrest)-Gruppe oder CO- (niederer Alkoxyrest)-Gruppe;
m = 0 oder 1; und
n = 0, 1, 2, 3, 4 oder 5;
wobei die Verbindung ein SERT/DAT-Selektivitätsverhältnis von mindestens 3 hat.1. Connection with the structural formula:
in which:
R 1 = COOCH 3 -, COR 3 -, lower alkyl, lower alkenyl, lower alkynyl, CONHR 4 - or COR 6 group;
R 2 = 6α, 6β, 7α or 7β substituent from the following group: H, OH, OR 3 , F, Cl, Br and NHR 3 ;
X = CH 2 , CHY, CYY 1 , CO, O, S, SO, SO 2 group or C = CX 1 Y, where the C, O or S atom is a component of Is ring;
X 1 = NR 3 , CH 2 , CHY, CYY 1 , CO, O, S, SO, SO 2 or NSO 2 R 3 group;
R 3 = H, (CH 2 ) n C 6 H 4 Y, C 6 H 4 Y, CHCH 2 , lower alkyl, lower alkenyl or never alkynyl group;
Y and Y 1 = H, Br, Cl, I, F, OH -, OCH 3 -, CF 3 -, NO 2 -, NH 2 -, CN, NHCOCH 3 -, N (CH 3 ) 2 -, (CH 2 ) n CH 3 -, COCH 3 - or C (CH 3 ) 3 group;
R 4 = CH 3 , CH 2 CH 3 or CH 3 SO 2 group;
R 6 = morpholinyl or piperidinyl group;
Ar = phenyl R 5 , naphthyl R 5 , anthracenyl R 5 , phenanthrenyl R 5 or diphenyl methoxy R 5 group;
R 5 = Br-, Br-, CI-, I-, F-, OCH 3 -, GF 3 -, NO 2 -, NH 2 -, CN-, NHCOCH 3 -, N (CH 3 ) 2 -, ( CH 2 ) n CH 3 -, COCH 3 -, C (CH 3 ) 3 -, where n = 0-6, 4-F-, 4-Cl-, 4-I-, 2-F-, 2-Cl -, 2-I-, 3-F-, 3-Cl-, 3-I-, 3,4-diCl-, 3,4-diOH-, 3,4-diOAc-, 3,4-diOCH 3 - , 3-OH - 4-Cl-, 3-OH - 4-F-, 3-Cl-4-OH-, 3-F-4-OH-; lower alkyl, lower alkoxy, lower alkenyl, lower alkynyl, CO (lower alkyl group) or CO (lower alkoxy group);
m = 0 or 1; and
n = 0, 1, 2, 3, 4 or 5;
wherein the compound has a SERT / DAT selectivity ratio of at least 3.
wobei:
R1 = COOCH3-, COR3-, niedere Alkyl-, niedere Alkenyl-, niedere Alkinyl-, CONHR4- oder COR6-Gruppe;
R2 = 6α-, 6β-, 7α- oder 7β-Substituent aus folgender Gruppe: H, OH, OR3, F, Cl, Br und NHR3;
X = CH2-, CHY-, CYY1-, CO-, O-, S-, SO-, SO2-Gruppe oder C=CX1Y, wobei das C-, O- oder 5-Atom ein Bestandteil des Rings ist;
X1 = NR3-, CH2-, CHY-, CYY1-, CO-, O-, S-, SO-, SO2- oder NSO2R3-Gruppe;
R3 = H-, (CH2)nC6H4Y-, C6H4Y-, CHCH2-, niedere Alkyl-, niedere Alkenyl- oder nie dere Alkinylgruppe;
Y und Y1 = H-, Br-, Cl-, I-, F-, OH-, OCH3-, CF3-, NO2-, NHz-, CN-, NHCOCH3-, N(CH3)2-, (CH2)nCH3-, COCH3- oder C(CH3)3-Gruppe;
R4 = CH3-, CH2CH3- oder CH3SO2-Gruppe;
R6 = Morpholinyl- oder Piperidinylgruppe;
Ar = Phenyl-R5-, Naphthyl-R5-, Anthracenyl-R5-, Phenanthrenyl-R5- oder Diphenyl methoxy-R5-Gruppe;
R5 = Br-, Cl-, I-, F-, OH-, OCH3-, CF3-, NO2-, NH2-, CN-, NHCOCH3-, N(CH3)2-, (CH2)nCH3-, COCH3-, C(CH3)3-, wobei n = 0-6, 4-F-, 4-Cl-, 4-I-, 2-F-, 2-Cl-, 2-I-, 3-F-, 3-Cl-, 3-I-, 3,4-diCl-, 3,4-diOH-, 3,4-diOAc-, 3,4-diOCH3-, 3-OH-4-Cl-, 3-OH-4-F-, 3-Cl-4-OH-, 3- F-4-OH-, niedere Alkyl-, niedere Alkoxy-, niedere Alkenyl-, niedere Alkinyl-, CO- (niederer Alkylrest)-Gruppe oder CO- (niederer Alkoxyrest)-Gnippe;
m = 0 oder 1; und
n = 0, 1, 2, 3, 4 oder 5;
wobei die Verbindung eine Affinität (K; ) zu dem SERT von weniger als etwa 500 nM besitzt.5. Connection with the structural formula:
in which:
R 1 = COOCH 3 -, COR 3 -, lower alkyl, lower alkenyl, lower alkynyl, CONHR 4 - or COR 6 group;
R 2 = 6α, 6β, 7α or 7β substituent from the following group: H, OH, OR 3 , F, Cl, Br and NHR 3 ;
X = CH 2 , CHY, CYY 1 , CO, O, S, SO, SO 2 group or C = CX 1 Y, where the C, O or 5 atom is a component of the Is ring;
X 1 = NR 3 , CH 2 , CHY, CYY 1 , CO, O, S, SO, SO 2 or NSO 2 R 3 group;
R 3 = H, (CH 2 ) n C 6 H 4 Y, C 6 H 4 Y, CHCH 2 , lower alkyl, lower alkenyl or never alkynyl group;
Y and Y 1 = H-, Br-, Cl-, I-, F-, OH-, OCH 3 -, CF 3 -, NO 2 -, NHz-, CN-, NHCOCH 3 -, N (CH 3 ) 2 -, (CH 2 ) n CH 3 -, COCH 3 - or C (CH 3 ) 3 group;
R 4 = CH 3 , CH 2 CH 3 or CH 3 SO 2 group;
R 6 = morpholinyl or piperidinyl group;
Ar = phenyl R 5 , naphthyl R 5 , anthracenyl R 5 , phenanthrenyl R 5 or diphenyl methoxy R 5 group;
R 5 = Br-, Cl-, I-, F-, OH-, OCH 3 -, CF 3 -, NO 2 -, NH 2 -, CN-, NHCOCH 3 -, N (CH 3 ) 2 -, ( CH 2 ) n CH 3 -, COCH 3 -, C (CH 3 ) 3 -, where n = 0-6, 4-F-, 4-Cl-, 4-I-, 2-F-, 2-Cl -, 2-I-, 3-F-, 3-Cl-, 3-I-, 3,4-diCl-, 3,4-diOH-, 3,4-diOAc-, 3,4-diOCH 3 - , 3-OH-4-Cl-, 3-OH-4-F-, 3-Cl-4-OH-, 3-F-4-OH-, lower alkyl, lower alkoxy, lower alkenyl, lower Alkynyl, CO (lower alkyl group) or CO (lower alkoxy group);
m = 0 or 1; and
n = 0, 1, 2, 3, 4 or 5;
wherein the compound has an affinity (K;) for the SERT of less than about 500 nM.
- a) 2β-Carbomethoxy-3β-(4'-propinylphenyl))-8-oxabicyclo[3.2.1] octan;
- b) (1R,1S)-2β-Carbomethoxy-3α-(4'-propinylphenyl)-8-oxabicyclo[3.2.1]octan;
- c) 2β-Carbomethoxy-3α-(4-isopropenylphenyl)-8-oxabicyclo [3.2.1]octan;
- d) 2β-Carbomethoxy-3β-(4-isopropenylphenyl)-8-oxabicyclo [3.2.1]octan;
- e) 2β-Carbomethoxy-3β-(4-isopropenylphenyl)-8-oxabicyclo[3.2.1]octan.
- a) 2β-carbomethoxy-3β- (4'-propynylphenyl)) - 8-oxabicyclo [3.2.1] octane;
- b) (1R, 1S) -2β-carbomethoxy-3α- (4'-propynylphenyl) -8-oxabicyclo [3.2.1] octane;
- c) 2β-carbomethoxy-3α- (4-isopropenylphenyl) -8-oxabicyclo [3.2.1] octane;
- d) 2β-carbomethoxy-3β- (4-isopropenylphenyl) -8-oxabicyclo [3.2.1] octane;
- e) 2β-Carbomethoxy-3β- (4-isopropenylphenyl) -8-oxabicyclo [3.2.1] octane.
- a) 2β-Carbomethoxy-3β-(3,4-dichlorophenyl)-8-oxabicyclo[3.2.1]octan;
- b) 2β-Carbomethoxy-3β-(3,4-dichlorophenyl)-bicyclo[3.2.1] octan;
- c) 2β-Carbomethoxy-3β-(4'-propinylphenyl)-8-oxabicyclo[3.2.1]octan;
- d) 2β-Carbomethoxy-3α-(4'-propinylphenyl)-8-oxabicyclo[3.2.1]octan;
- e) 2β-Carbomethoxy-3β-(2-naphthyl)-8-bicyclo[3.2.1]octan;
- f) 2β-Carbomethoxy-3α-(2-naphthyl)-8-bicyclo[3.2.1]octan;
- g) 2β-Carbomethoxy-3α-(4-isopropenylphenyl)-8-oxabicyclo[3.2.1] octan;
- h) 2β-Carbomethoxy-3β-(4-isopropenylphenyl)-8-oxabicyclo[3.2.1]octan;
- i) 2β-Carbomethoxy-3β-(4-isopropenylphenyl)-8-oxabicyclo[3.2.1]octan.
- a) 2β-carbomethoxy-3β- (3,4-dichlorophenyl) -8-oxabicyclo [3.2.1] octane;
- b) 2β-carbomethoxy-3β- (3,4-dichlorophenyl) bicyclo [3.2.1] octane;
- c) 2β-carbomethoxy-3β- (4'-propynylphenyl) -8-oxabicyclo [3.2.1] octane;
- d) 2β-carbomethoxy-3α- (4'-propynylphenyl) -8-oxabicyclo [3.2.1] octane;
- e) 2β-carbomethoxy-3β- (2-naphthyl) -8-bicyclo [3.2.1] octane;
- f) 2β-carbomethoxy-3α- (2-naphthyl) -8-bicyclo [3.2.1] octane;
- g) 2β-carbomethoxy-3α- (4-isopropenylphenyl) -8-oxabicyclo [3.2.1] octane;
- h) 2β-carbomethoxy-3β- (4-isopropenylphenyl) -8-oxabicyclo [3.2.1] octane;
- i) 2β-Carbomethoxy-3β- (4-isopropenylphenyl) -8-oxabicyclo [3.2.1] octane.
hat, wobei
X = O-, CH2-, CHY-, CYY1-, CO-Gruppe oder C=CX1Y;
R7 = niedere Alkenyl- oder niedere Alkinylgruppe mit etwa 2 bis etwa 8 Kohlenstoff atomen; und
R8 = H, Br-, Cl-, I-, F-, OH-, OCH3-, CF3-, NO2-, NHz-, CN-, NHCOCH3-, N(CH3)2-, (CH2)nCH3-, COCH3- oder C(CH3)3-Gruppe, wobei n = 0-6.12. The compound of claim 1, wherein the compound has the structural formula
has, where
X = O, CH 2 , CHY, CYY 1 , CO group or C = CX 1 Y;
R 7 = lower alkenyl or lower alkynyl group with about 2 to about 8 carbon atoms; and
R 8 = H, Br-, Cl-, I-, F-, OH-, OCH 3 -, CF 3 -, NO 2 -, NH z -, CN-, NHCOCH 3 -, N (CH 3 ) 2 - , (CH 2 ) n CH 3 -, COCH 3 - or C (CH 3 ) 3 group, where n = 0-6.
hat, wobei
X = O-, CH2-, CHY-, CYY1-, CO-Gruppe oder C=CX1Y;
R7 = niedere Alkenyl- oder niedere Alkinylgruppe mit etwa 2 bis etwa 8 Kohlenstoff atomen; und
R8 = H, Br-, Cl-, I-, F-, OCH3-, CF3-, NO2-, NH2-, CN-, NHCOCH3-, N(CH3)2-, (CH2)nCH3-, COCH3- oder C(CH3)3-Gruppe, wobei n = 0-6.14. A compound according to claim 5, wherein the compound has the structural formula
has, where
X = O, CH 2 , CHY, CYY 1 , CO group or C = CX 1 Y;
R 7 = lower alkenyl or lower alkynyl group with about 2 to about 8 carbon atoms; and
R 8 = H, Br-, Cl-, I-, F-, OCH 3 -, CF 3 -, NO 2 -, NH 2 -, CN-, NHCOCH 3 -, N (CH 3 ) 2 -, (CH 2 ) n CH 3 , COCH 3 or C (CH 3 ) 3 group, where n = 0-6.
hat, wobei:
R1 = COOCH3-, COR3-, niedere Alkyl-, niedere Alkenyl-, niedere Alkinyl-, CONH4- oder COR6-Gruppe;
R2 = 6α-, 6β-, 7α- oder 7β-Substituent aus folgender Gruppe: H, OH, OR3, F, Cl, Br und NHR3;
X = CH2-, CHY-, CYY1-, CO-, O-, S-, SO-, SO2-Gruppe oder C = CX1Y, wobei das C-, O- oder S-Atom ein Bestandteil des Rings ist;
X1 = NR3-, CH2-, CHY-, CYY1-, CO-, O-, S-, SO-, SO2- oder NSO2R3-Gruppe;
R3 = H-, (CH2)nC6H4Y-, C6H4Y-, CHCH2-, niedere Alkyl-, niedere Alkenyl- oder nie dere Alkinylgruppe;
Y und Y1 = H-, Br-, Cl-, I-, F-, OH-, OCH3-, CF3-, NO2-, NH2-, CN-, NHCOCH3-, N(CH3)2-, (CH2)nCH3-, COCH3- oder C(CH3)3-Gruppe;
R4 = CH3-, CH2CH3- oder CH3SO2-Gruppe;
R6 = Morpholinyl- oder Piperidinylgruppe;
Ar = Phenyl-R5-, Naphthyl-R5-, Anthracenyl-R5-, Phenanthrenyl-R5- oder Diphenyl methoxy-R5-Gruppe;
R5 = Br-, Br-, Cl-, I-, F-, OCH3-, CF3-, NO2-, NH2-, CN-, NHCOCH3-, N(CH3)2-, (CH2)nCH3-, COCH3-, C(CH3)3-, wobei n = 0-6, 4-F-, 4-Cl-, 4-I-, 2-F-, 2-Cl-, 2-I-, 3-F-, 3-Cl-, 3-I-, 3,4-diCl-, 3,4-diOH-, 3,4-diOAc-, 3,4-diOCH3-, 3-OH-4-Cl-, 3-OH-4-F-, 3-Cl-4-OH-, 3- F-4-OH-, niedere Alkyl-, niedere Alkoxy-, niedere Alkenyl-, niedere Alkinyl-, CO- (niederer Alkylrest)-Gruppe oder CO- (niederer Alkoxyrest)-Gruppe;
m = 0 oder 1; und
n = 0, 1, 2, 3, 4 oder 5;
wobei die Verbindung ein SERT/DAT-Selektivitätsverhältnis von mindestens 3 hat.16. A pharmaceutical composition comprising a therapeutically effective amount of a pharmaceutically acceptable carrier and an effective amount of a compound having the structural formula
has, where:
R 1 = COOCH 3 -, COR 3 -, lower alkyl, lower alkenyl, lower alkynyl, CONH 4 - or COR 6 group;
R 2 = 6α, 6β, 7α or 7β substituent from the following group: H, OH, OR 3 , F, Cl, Br and NHR 3 ;
X = CH 2 , CHY, CYY 1 , CO, O, S, SO, SO 2 group or C = CX 1 Y, where the C, O or S atom is a component of Is ring;
X 1 = NR 3 , CH 2 , CHY, CYY 1 , CO, O, S, SO, SO 2 or NSO 2 R 3 group;
R 3 = H, (CH 2 ) n C 6 H 4 Y, C 6 H 4 Y, CHCH 2 , lower alkyl, lower alkenyl or never alkynyl group;
Y and Y 1 = H-, Br-, Cl-, I-, F-, OH-, OCH 3 -, CF 3 -, NO 2 -, NH 2 -, CN-, NHCOCH 3 -, N (CH 3 ) 2 -, (CH 2 ) n CH 3 -, COCH 3 - or C (CH 3 ) 3 group;
R 4 = CH 3 , CH 2 CH 3 or CH 3 SO 2 group;
R 6 = morpholinyl or piperidinyl group;
Ar = phenyl R 5 , naphthyl R 5 , anthracenyl R 5 , phenanthrenyl R 5 or diphenyl methoxy R 5 group;
R 5 = Br-, Br-, Cl-, I-, F-, OCH 3 -, CF 3 -, NO 2 -, NH 2 -, CN-, NHCOCH 3 -, N (CH 3 ) 2 -, ( CH 2 ) n CH 3 -, COCH 3 -, C (CH 3 ) 3 -, where n = 0-6, 4-F-, 4-Cl-, 4-I-, 2-F-, 2-Cl -, 2-I-, 3-F-, 3-Cl-, 3-I-, 3,4-diCl-, 3,4-diOH-, 3,4-diOAc-, 3,4-diOCH 3 - , 3-OH-4-Cl-, 3-OH-4-F-, 3-Cl-4-OH-, 3-F-4-OH-, lower alkyl, lower alkoxy, lower alkenyl, lower Alkynyl, CO (lower alkyl group) or CO (lower alkoxy group);
m = 0 or 1; and
n = 0, 1, 2, 3, 4 or 5;
wherein the compound has a SERT / DAT selectivity ratio of at least 3.
hat, wobei:
R1 = COOCH3-, COR3-, niedere Alkyl-, niedere Alkenyl-, niedere Alkinyl-, CONHR1- oder COR6-Gruppe;
R2 = 6α-, 6β-, 7a- oder 7β-Substituent aus folgender Gruppe: H, OH, OR3, F, Cl, Br und NHR3;
X = CH2-, CHY-, CYY1-, CO-, O-, S-, SO-, SO2-Gruppe oder C=CX1Y, wobei das C-, O- oder S-Atom ein Bestandteil des Rings ist;
X1 = NR3-, CH2- , CHY-, CYY1-, CO-, O-, S-, SO-, SO2- oder NSO2R3-Gruppe;
R3 = H-, (CH2)nC6H4Y-, C6H4Y-, CHCH2-, niedere Alkyl-, niedere Alkenyl- oder nie dere Alkinylgruppe;
Y und Y1 = H-, Br-, Cl-, I-, F-, OH-, OCH3-, CF3-, NO2-, NH2, CN-, NHCOCH3-, N(CH3)2-, (CH2)nCH3-, COCH3- oder C(CH3)3-Gruppe;
R5 = CH3-, CH2CH3- oder CH3SO2-Gruppe;
R6 = Morpholinyl- oder Piperidinylgruppe;
Ar = Phenyl-R5-, Naphthyl-R5-, Anthracenyl-R5-, Phenanthrenyl-R5- oder Diphenyl methoxy-R5-Gruppe;
R5 = Br-, Cl-, I-, F-, OH-, OCH3-, CF3-, NO2-, NH2-, CN-, NHCOCH3-, N(CH3)2-, (CH2)nCH3-, COCH3-, C(CH3)3-, wobei n = 0-6, 4-F-, 4-Cl-, 4-I-, 2-F-, 2-Cl-, 2-I-, 3-F-, 3-Cl-, 3-I-, 3,4-diCl-, 3,4-diOH-, 3,4-diOAc-, 3,4-diOCH3-, 3-OH-4-Cl-, 3-OH-4-F-, 3-Cl-4-OH-, 3- F-4-OH-, niedere Alkyl-, niedere Alkoxy-, niedere Alkenyl-, niedere Alkinyl-, CO- (niederer Alkylrest)-Gruppe oder CO- (niederer Alkoxyrest)-Gruppe;
m = 0 oder 1; und
n = 0, 1, 2, 3, 4 oder 5;
wobei die Verbindung eine Affinität (Ki) zu dem SERT von weniger als etwa 500 nM
besitzt.17. A pharmaceutical composition comprising a therapeutically effective amount of a pharmaceutically acceptable carrier and an effective amount of a compound having the structural formula
has, where:
R 1 = COOCH 3 -, COR 3 -, lower alkyl, lower alkenyl, lower alkynyl, CONHR 1 - or COR 6 group;
R 2 = 6α, 6β, 7a or 7β substituent from the following group: H, OH, OR 3 , F, Cl, Br and NHR 3 ;
X = CH 2 , CHY, CYY 1 , CO, O, S, SO, SO 2 group or C = CX 1 Y, where the C, O or S atom is a component of Is ring;
X 1 = NR 3 , CH 2 , CHY, CYY 1 , CO, O, S, SO, SO 2 or NSO 2 R 3 group;
R 3 = H, (CH 2 ) n C 6 H 4 Y, C 6 H 4 Y, CHCH 2 , lower alkyl, lower alkenyl or never alkynyl group;
Y and Y 1 = H, Br, Cl, I, F, OH, OCH 3 , CF 3 , NO 2 , NH 2 , CN, NHCOCH 3 , N (CH 3 ) 2 -, (CH 2 ) n CH 3 -, COCH 3 - or C (CH 3 ) 3 group;
R 5 = CH 3 -, CH 2 CH 3 - or CH 3 SO 2 group;
R 6 = morpholinyl or piperidinyl group;
Ar = phenyl R 5 , naphthyl R 5 , anthracenyl R 5 , phenanthrenyl R 5 or diphenyl methoxy R 5 group;
R 5 = Br-, Cl-, I-, F-, OH-, OCH 3 -, CF 3 -, NO 2 -, NH 2 -, CN-, NHCOCH 3 -, N (CH 3 ) 2 -, ( CH 2 ) n CH 3 -, COCH 3 -, C (CH 3 ) 3 -, where n = 0-6, 4-F-, 4-Cl-, 4-I-, 2-F-, 2-Cl -, 2-I-, 3-F-, 3-Cl-, 3-I-, 3,4-diCl-, 3,4-diOH-, 3,4-diOAc-, 3,4-diOCH 3 - , 3-OH-4-Cl-, 3-OH-4-F-, 3-Cl-4-OH-, 3-F-4-OH-, lower alkyl, lower alkoxy, lower alkenyl, lower Alkynyl, CO (lower alkyl group) or CO (lower alkoxy group);
m = 0 or 1; and
n = 0, 1, 2, 3, 4 or 5;
wherein the compound has an affinity (K i ) for the SERT of less than about 500 nM
has.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32853201P | 2001-10-11 | 2001-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE20203103U1 true DE20203103U1 (en) | 2002-07-11 |
Family
ID=23281370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE20203103U Expired - Lifetime DE20203103U1 (en) | 2001-10-11 | 2002-02-27 | Serotonin reuptake inhibitors |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP4071012B2 (en) |
KR (2) | KR20030030817A (en) |
CA (2) | CA2373559C (en) |
DE (1) | DE20203103U1 (en) |
GB (1) | GB2380733A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1429811A1 (en) * | 2001-08-17 | 2004-06-23 | President And Fellows Of Harvard College | Theurapeutic tropane compounds |
EP1478356A2 (en) * | 2002-02-08 | 2004-11-24 | President And Fellows Of Harvard College | Therapeutic compounds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5496953A (en) * | 1990-08-09 | 1996-03-05 | Research Triangle Institute | Cocaine receptor binding ligands |
US5770180A (en) * | 1992-08-24 | 1998-06-23 | Organix, Inc. | Bridge-substituted tropanes for methods of imaging and therapy |
US5948933A (en) * | 1997-07-11 | 1999-09-07 | Organix, Inc. | Tropane analogs and methods for inhibition of monoamine transport |
ZA971525B (en) * | 1996-02-22 | 1997-10-21 | Neurosearch As | Tropane derivatives, their preparation and use. |
-
2002
- 2002-02-27 KR KR1020020010386A patent/KR20030030817A/en active Application Filing
- 2002-02-27 GB GB0204596A patent/GB2380733A/en not_active Withdrawn
- 2002-02-27 DE DE20203103U patent/DE20203103U1/en not_active Expired - Lifetime
- 2002-02-27 CA CA2373559A patent/CA2373559C/en not_active Expired - Fee Related
- 2002-02-27 JP JP2002051488A patent/JP4071012B2/en not_active Expired - Fee Related
- 2002-02-27 CA CA002506646A patent/CA2506646A1/en not_active Abandoned
-
2009
- 2009-01-09 KR KR1020090001827A patent/KR20090010133A/en not_active Application Discontinuation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1429811A1 (en) * | 2001-08-17 | 2004-06-23 | President And Fellows Of Harvard College | Theurapeutic tropane compounds |
EP1429811A4 (en) * | 2001-08-17 | 2006-05-17 | Harvard College | Theurapeutic tropane compounds |
EP1478356A2 (en) * | 2002-02-08 | 2004-11-24 | President And Fellows Of Harvard College | Therapeutic compounds |
EP1478356A4 (en) * | 2002-02-08 | 2005-03-16 | Harvard College | Therapeutic compounds |
US7439264B2 (en) | 2002-02-08 | 2008-10-21 | President And Fellows Of Harvard College | Therapeutic compounds |
Also Published As
Publication number | Publication date |
---|---|
CA2373559C (en) | 2010-07-27 |
CA2506646A1 (en) | 2003-04-11 |
KR20090010133A (en) | 2009-01-28 |
KR20030030817A (en) | 2003-04-18 |
JP2003176254A (en) | 2003-06-24 |
CA2373559A1 (en) | 2003-04-11 |
GB2380733A (en) | 2003-04-16 |
JP4071012B2 (en) | 2008-04-02 |
GB0204596D0 (en) | 2002-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3879555A (en) | Method of treating drug addicts | |
CA2143864A1 (en) | Morphinan derivatives and pharmaceutical use thereof | |
Costello et al. | A novel series of potent and selective agonists at the opioid κ-receptor | |
HK18696A (en) | Peptides having tachykinin antagonist activity a process for preparation thereof and pharmaceutical compositions comprising the same | |
EP0534628A1 (en) | Compositions comprising a tramadol material and any of codeine, oxycodone or hydrocodone, and their use | |
CA2233285A1 (en) | Pyrazolopyrimidines as crf receptor antagonists | |
CA2358998A1 (en) | Substituted bicyclic derivatives useful as anticancer agents | |
HK1003708A1 (en) | Peripheral vasodilating agent containing n-acylated 4-amino piperidine derivatives as active ingredients | |
CA2341690A1 (en) | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | |
CA2098076A1 (en) | Imidate prodrugs of pharmaceutically useful anticonvulsant sulfamates | |
CA2073981A1 (en) | 2-arylthiazole derivatives and pharmaceutical composition thereof | |
CA2333703A1 (en) | Isothiazole derivatives useful as anticancer agents | |
WO2001055119A3 (en) | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | |
EP0915094A4 (en) | Morphinane derivatives and medicinal use thereof | |
Fredericks et al. | Comparative in vitro effects of imipramine, oxybutynin, and flavoxate on rabbit detrusor | |
IE780515L (en) | Morphine derivatives | |
PL313480A1 (en) | Crystalline anhydrous mophethyl mycophenolate and pharmaceutical agent for intravenous administration | |
CA2036716A1 (en) | Disinfectant concentrate and its use as a mycobactericide viricide | |
ES2087038A1 (en) | Novel piperidine derivatives with paf antagonist activity | |
DK0458207T3 (en) | ||
EP1219624A4 (en) | Remedies for neuropathic pain and model animals of neuropathic pain | |
CA2109435A1 (en) | Compositions of N-(Phosphonoacetyl)-L-Aspartic Acid and Methods of Their Use as Broad Spectrum Antivirals | |
DE20203103U1 (en) | Serotonin reuptake inhibitors | |
GR3025207T3 (en) | 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents | |
EP0801065A4 (en) | 1,4-dihydropyridine compound and medicinal composition containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R207 | Utility model specification |
Effective date: 20020814 |
|
R150 | Utility model maintained after payment of first maintenance fee after three years |
Effective date: 20050415 |
|
R151 | Utility model maintained after payment of second maintenance fee after six years |
Effective date: 20080424 |
|
R152 | Utility model maintained after payment of third maintenance fee after eight years |
Effective date: 20100319 |
|
R071 | Expiry of right | ||
R071 | Expiry of right |